169 related articles for article (PubMed ID: 30178083)
21. Development and validation of a reporter gene assay to determine the bioactivity of anti-CTLA-4 monoclonal antibodies.
Liu C; Yu C; Yang Y; Cui Y; Zhang F; Wang L; Wang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108277. PubMed ID: 34773758
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a reporter gene assay for bioactivity determination of Anti-CGRP monoclonal antibodies.
Guo X; Yu C; Wang L; Zhang F; Wang K; Huang J; Wang J
Anal Biochem; 2021 Dec; 634():114291. PubMed ID: 34161831
[TBL] [Abstract][Full Text] [Related]
24. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract][Full Text] [Related]
26. Discovery of IL-6 and Development of Anti-IL-6R Antibody.
Kishimoto T
Keio J Med; 2019; 68(4):96. PubMed ID: 31875623
[TBL] [Abstract][Full Text] [Related]
27. To determine the bioactivity of IL-1β monoclonal antibodies: Introduction of a reliable reporter gene assay.
Chen S; Fu Z; Yu C; Liu C; Li M; Wu G; Guo X; Liu X; Wang L; Wang J
Anal Sci Adv; 2023 Oct; 4(9-10):282-292. PubMed ID: 38715593
[TBL] [Abstract][Full Text] [Related]
28. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy.
Atreya R; Billmeier U; Rath T; Mudter J; Vieth M; Neumann H; Neurath MF
World J Gastroenterol; 2015 Dec; 21(45):12963-9. PubMed ID: 26668517
[TBL] [Abstract][Full Text] [Related]
29. Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies.
Wang L; Yu C; Yang Y; Gao K; Wang J
J Pharm Biomed Anal; 2017 Oct; 145():447-453. PubMed ID: 28735186
[TBL] [Abstract][Full Text] [Related]
30. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
31. Establishment of a novel cell-based assay for screening small molecule antagonists of human interleukin-6 receptor.
He YY; Yan Y; Zhang C; Li PY; Wu P; Du P; Zeng DD; Fang JS; Wang S; Du GH
Acta Pharmacol Sin; 2014 Nov; 35(11):1453-62. PubMed ID: 25345743
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
33. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
Mihara M; Ohsugi Y; Kishimoto T
Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis.
Thiolat A; Semerano L; Pers YM; Biton J; Lemeiter D; Portales P; Quentin J; Jorgensen C; Decker P; Boissier MC; Louis-Plence P; Bessis N
Arthritis Rheumatol; 2014 Feb; 66(2):273-83. PubMed ID: 24504799
[TBL] [Abstract][Full Text] [Related]
35. Methods for treating IL-6-related diseases (US2015010554A1): a patent evaluation.
Chin YW
Expert Opin Ther Pat; 2015; 25(9):1065-8. PubMed ID: 26059273
[TBL] [Abstract][Full Text] [Related]
36. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
Hashizume M; Hayakawa N; Mihara M
Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
[TBL] [Abstract][Full Text] [Related]
37. A simple and robust reporter gene assay for measuring the bioactivity of anti-RANKL therapeutic antibodies.
Yu C; Wang L; Ni Y; Wang J
RSC Adv; 2019 Dec; 9(69):40196-40202. PubMed ID: 35542634
[TBL] [Abstract][Full Text] [Related]
38. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
39. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
40. Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
Yi H; Cho HJ; Cho SM; Jo K; Park JA; Kim NH; Amidon GL; Kim JS; Shin HC
Int J Oncol; 2012 Jul; 41(1):310-6. PubMed ID: 22552503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
